Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology

Hoenigl, Martin, Salmanton-García, Jon, Walsh, Thomas J, Nucci, Marcio, Neoh, Chin Fen, Jenks, Jeffrey D, Lackner, Michaela, Sprute, Rosanne, Al-Hatmi, Abdullah M S, Bassetti, Matteo, Carlesse, Fabianne, Freiberger, Tomas, Koehler, Philipp, Lehrnbecher, Thomas, Kumar, Anil, Prattes, Juergen, Richardson, Malcolm, Revankar, Sanjay, Slavin, Monica A, Stemler, Jannik, Spiess, Birgit, Taj-Aldeen, Saad J, Warris, Adilia, Woo, Patrick C Y, Young, Jo-Anne H, Albus, Kerstin, Arenz, Dorothee, Arsic-Arsenijevic, Valentina, Bouchara, Jean-Philippe, Chinniah, Terrence Rohan, Chowdhary, Anuradha, de Hoog, G Sybren, Dimopoulos, George, Duarte, Rafael F, Hamal, Petr, Meis, Jacques F, Mfinanga, Sayoki, Queiroz-Telles, Flavio, Patterson, Thomas F, Rahav, Galia, Rogers, Thomas R, Rotstein, Coleman, Wahyuningsih, Retno, Seidel, Danila and Cornely, Oliver A (2021) 'Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology'. Lancet Infectious Diseases, Vol 21, Issue 8, e246-e257.

Full text not available from this repository.

Abstract

With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown effectiveness in preventing many invasive fungal infections, selective pressure has caused an increase of breakthrough infections caused by Fusarium, Lomentospora, and Scedosporium species, as well as by dematiaceous moulds, Rasamsonia, Schizophyllum, Scopulariopsis, Paecilomyces, Penicillium, Talaromyces and Purpureocillium species. Guidance on the complex multidisciplinary management of infections caused by these pathogens has the potential to improve prognosis. Management routes depend on the availability of diagnostic and therapeutic options. The present recommendations are part of the One World—One Guideline initiative to incorporate regional differences in the epidemiology and management of rare mould infections. Experts from 24 countries contributed their knowledge and analysed published evidence on the diagnosis and treatment of rare mould infections. This consensus document intends to provide practical guidance in clinical decision making by engaging physicians and scientists involved in various aspects of clinical management. Moreover, we identify areas of uncertainty and constraints in optimising this management.

Item Type:	Article
Subjects:	QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 252 Antifungal agents. Antifungal antibiotics QW Microbiology and Immunology > Fungi. Pathogenic Fungi. > QW 180 Pathogenic Fungi QW Microbiology and Immunology > Reference Works. General Immunology > QW 504 General works WA Public Health > Health Administration and Organization > WA 530 International health administration
Faculty: Department:	Clinical Sciences & International Health > International Public Health Department
Digital Object Identifer (DOI):	https://doi.org/10.1016/S1473-3099(20)30784-2
Depositing User:	Stacy Murtagh
Date Deposited:	22 Feb 2021 15:45
Last Modified:	24 Jun 2022 10:29
URI:	https://archive.lstmed.ac.uk/id/eprint/17032

Statistics

View details

Actions (login required)

Edit Item